Mapping and understanding alveolar cells in smokers with COPD
Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease
NA · Centre Hospitalier Intercommunal Creteil · NCT05227547
This study is trying to understand how certain lung cells behave in smokers with COPD compared to non-smokers to learn more about how smoking affects lung repair.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 186 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Intercommunal Creteil (other) |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Créteil and 3 other locations) |
| Trial ID | NCT05227547 on ClinicalTrials.gov |
What this trial studies
This study evaluates the regenerative abilities of mesenchymal cells in the alveolar type 2 cells of patients undergoing thoracic surgery for suspected cancer. It focuses on smokers with and without chronic obstructive pulmonary disease (COPD) and compares them to non-smokers. The research aims to uncover the mechanisms behind the depletion of alveolar progenitor cells and their role in the pathophysiology of COPD. By analyzing the interactions between different cell populations in the alveolar stem cell niche, the study seeks to provide insights into lung repair processes affected by smoking and COPD.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are undergoing lung resection surgery for cancer or suspected cancer and are smokers with or without COPD.
Not a fit: Patients with chronic autoimmune diseases, those undergoing neo-adjuvant chemotherapy, or individuals who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies for enhancing lung repair in patients with COPD.
How similar studies have performed: While similar studies have explored cell interactions in lung diseases, this specific approach to mapping alveolar cells in smokers with COPD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 2. Patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer 3. Acceptance to participate in the protocol 4. Affiliated to a social security plan Exclusion Criteria: 1. Chronic autoimmune disease 2. Patient under guardianship or curators 3. Neo-adjuvant chemotherapy 4. History of thoracic radiotherapy 5. Pregnant woman 6. Minor patient 7. Person not able to consent 8. Person deprived of liberty
Where this trial is running
Créteil and 3 other locations
- Rousseau-Bussac — Créteil, France (RECRUITING)
- Hopital Cochin — Paris, France (ACTIVE_NOT_RECRUITING)
- HEGP — Paris, France (ACTIVE_NOT_RECRUITING)
- Hopital Tenon — Paris, France (ACTIVE_NOT_RECRUITING)
Study contacts
- Study coordinator: JUNG Camille, MD
- Email: camille.jung@chiccreteil.fr
- Phone: 0145175000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Obstructive Lung Disease, Chronic Obstructive Pulmonary Disease